Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin and UDCA in Liver Cirrhosis
NCT07102979Terminated
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ursodeoxycholic acid and simvastatin in Liver Fibrosis (LF) (5 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoints: Change in liver fibrosis biomarker (TGF-β1) at 6 months and Change in liver fibrosis biomarker (Type IV collagen) at 6 months. Started Jan 2024; status: terminated.
02
Drugs
ursodeoxycholic acidsimvastatin
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07102979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102979.